Avanir Pharmaceuticals Inc (NASDAQ:AVNR)

6.22
Data as of Aug 29
 +0.21 / +3.49%
Today’s Change
2.62
Today|||52-Week Range
6.24
+85.12%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.0B

Company Description

Avanir Pharmaceuticals, Inc. is a pharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The company's products are NUEDEXTA, AVP-923, Deuterated Dextromethorphan, ABREVA and Thravixa. Avanir Pharmaceuticals was founded on August 31, 1988 and headquartered in Aliso Viejo, CA.

Contact Information

Avanir Pharmaceuticals, Inc.
20 Enterprise
Aliso Viejo California 92656
P:(949) 389-6700
Investor Relations:
(949) 389-6737

Employees

Shareholders

Other institutional38.56%
Mutual fund holders36.28%
Individual stakeholders12.50%

Top Executives

Keith A. KatkinPresident, Chief Executive Officer & Director
Christine G. OcampoSecretary & Vice President-Finance
Randall E. KayeChief Medical Officer & SVP-Medical Affairs
Joao SiffertCSO, Senior VP-Research & Development
Rohan PalekarChief Commercial Officer & Senior Vice President

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.